BCMA-CD3 BISPECIFIC

Clinical trials for BCMA-CD3 BISPECIFIC explained in plain language.

Never miss a new study

Get alerted when new BCMA-CD3 BISPECIFIC trials appear

Sign up with your email to follow new studies for BCMA-CD3 BISPECIFIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for patients out of options: immune therapy tested for aggressive blood cancer

Disease control Completed

This study tested a new drug called Elranatamab for Chinese patients with a severe form of multiple myeloma that no longer responds to standard treatments. The drug is an injection that works by activating the body's own immune system to attack the cancer cells. The trial had two…

Matched conditions: BCMA-CD3 BISPECIFIC

Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

BCMA-CD3 BISPECIFIC

Get alerted when new BCMA-CD3 BISPECIFIC trials appear

New hope for patients out of options: immune therapy tested for aggressive blood cancer